The pathological types of patients with SMARCA4‐dNSCLC were adenocarcinoma (74%), squamous cell carcinoma (10%), poorly differentiated carcinoma (14%), sarcomatoid carcinoma (1%), and neuroendocrine carcinoma (1%). This evidence concerns the gene SMARCA4 and sarcomatoid carcinoma.